|
Name |
Beauvericin D
|
Molecular Formula | C44H55N3O9 | |
IUPAC Name* |
(3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-4,10-dimethyl-6,12,18-tri(propan-2-yl)-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone
|
|
SMILES |
CC(C)[C@@H]1C(=O)N[C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O[C@@H](C(=O)N([C@H](C(=O)O1)CC2=CC=CC=C2)C)C(C)C)CC3=CC=CC=C3)C)C(C)C)CC4=CC=CC=C4
|
|
InChI |
InChI=1S/C44H55N3O9/c1-27(2)36-39(48)45-33(24-30-18-12-9-13-19-30)42(51)55-37(28(3)4)40(49)47(8)35(26-32-22-16-11-17-23-32)44(53)56-38(29(5)6)41(50)46(7)34(43(52)54-36)25-31-20-14-10-15-21-31/h9-23,27-29,33-38H,24-26H2,1-8H3,(H,45,48)/t33-,34-,35-,36+,37+,38+/m0/s1
|
|
InChIKey |
CPKHOIZGUQVKAF-YAQJXRFXSA-N
|
|
Synonyms |
Beauvericin D; (3S,6R,9S,12R,15S,18R)-3,9,15-tribenzyl-6,12,18-triisopropyl-4,10-dimethyl-1,7,13-trioxa-4,10,16-triazacyclooctadecane-2,5,8,11,14,17-hexone
|
|
CAS | NA | |
PubChem CID | 3007986 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 769.9 | ALogp: | 8.2 |
HBD: | 1 | HBA: | 9 |
Rotatable Bonds: | 9 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 149.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 56 | QED Weighted: | 0.233 |
Caco-2 Permeability: | -5.145 | MDCK Permeability: | 0.00010931 |
Pgp-inhibitor: | 1 | Pgp-substrate: | 0.001 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.017 |
30% Bioavailability (F30%): | 0.175 |
Blood-Brain-Barrier Penetration (BBB): | 0.007 | Plasma Protein Binding (PPB): | 96.16% |
Volume Distribution (VD): | 1.002 | Fu: | 0.89% |
CYP1A2-inhibitor: | 0.008 | CYP1A2-substrate: | 0.033 |
CYP2C19-inhibitor: | 0.409 | CYP2C19-substrate: | 0.865 |
CYP2C9-inhibitor: | 0.535 | CYP2C9-substrate: | 0.108 |
CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.134 |
CYP3A4-inhibitor: | 0.782 | CYP3A4-substrate: | 0.914 |
Clearance (CL): | 4.612 | Half-life (T1/2): | 0.059 |
hERG Blockers: | 0.131 | Human Hepatotoxicity (H-HT): | 0.992 |
Drug-inuced Liver Injury (DILI): | 0.988 | AMES Toxicity: | 0.012 |
Rat Oral Acute Toxicity: | 0.874 | Maximum Recommended Daily Dose: | 0.573 |
Skin Sensitization: | 0.023 | Carcinogencity: | 0.032 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.005 |
Respiratory Toxicity: | 0.024 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002627 | 0.867 | D0J7XL | 0.333 | ||||
ENC004891 | 0.435 | D02XIY | 0.332 | ||||
ENC002483 | 0.399 | D0U4YG | 0.310 | ||||
ENC003692 | 0.386 | D03DEI | 0.308 | ||||
ENC003559 | 0.385 | D05MNW | 0.298 | ||||
ENC002857 | 0.384 | D07XGH | 0.298 | ||||
ENC002129 | 0.383 | D07DSQ | 0.288 | ||||
ENC000948 | 0.381 | D0E2OU | 0.287 | ||||
ENC002484 | 0.381 | D0U5GB | 0.279 | ||||
ENC002971 | 0.376 | D06TFE | 0.277 |